George Frodsham is the CEO and founder of MediSieve, a London based biotech that has developed a platform technology that enables the specific removal of harmful substances from the bloodstream. MediSieve’s technology is providing new solutions for a variety of clinical challenges across inflammation, cancer, gene therapies and others.
George spun out MediSieve from University College London following his PhD in biochemical engineering. He has received business and entrepreneurship training from the London Business School, the Royal Academy of Engineering, and the Royal Society of Edinburgh. In 2019, George was awarded the "Innovator of the Year" award by the Biotechnology and Biological Sciences Research Council and named one of MIT Tech Review's "30 under 30".